Rethinking Starting Material: Whole Blood For Autologous T-Cell Manufacture

Engineering Affordability Into Customizable Microscopy Platforms

Maximize Exosome Yields Using a Chemically Defined Bioreactor Media System

Maintaining Process Consistency And Performance During Scale-Up

Operationalizing Adaptive Design For FDA's One-Trial Era

Advancing Drug Product Manufacturing With A Risk-Based Approach

Using Analysis Software To Obtain Accurate Loading Concentrations

Precision At Scale: Optimizing Cell-Free DNA Manufacturing For mRNA Vaccines

Intensifying Cell Production Processes Through Real-Time Control

Determining ADCs Positional Isomer Distribution With Nonreduced CE-SDS

Developing Custom GMP Lipids: A Patient-Driven Partnership

Rethinking Starting Material: Whole Blood For Autologous T-Cell Manufacture

Maintaining Process Consistency And Performance During Scale-Up

Accelerating CHO Media Development: From Screening To AI Design

Evaluating Modular CAR T Manufacturing Workflows

Driving Productivity Across The Antibody Manufacturing Workflow

De-Risking Cell Culture Media Scale-Up For Late-Stage Manufacturing

Driving Measurable Productivity Gains In CHO Cell Culture

The Future Of Cell Culture Media Development

From Data To Decisions: AI And Multi-Omics For Cell Culture Development

How Modular Workflows Are Redefining CAR T Manufacturing

Reducing Particulate-Related Batch Risk In Bioprocessing

How Intensified Upstream Processing Improves Scale-Up And Tech Transfer

Generate Stable High-Producing Clones In 14 Weeks

Using Residual DNA Quantification Data To De-Risk mAb Development

Efficient mAb Development With A Flexible Purification Toolkit

CAR-T Strategy In 2026: Scaling Autologous, Advancing Allogeneic

Ori Spotlight: Building Early-Phase CGT Infrastructure For Translational Success

Plasmid Complexity And The Push For Stronger CGT Material Control

Validation Of An LCMS Hybrid Assay With EVOSEP Cleanup

An All-In-One Solution For Residual DNA Quantitation

Major Advancements In mRNA

Can You Run Crude Samples Using An SPR Instrument?

High Efficiency Cell Engineering From Concept To Clinic

Mitigate Clinical Risk In Cell Therapy Development With A GMP Compliant Process

Electroporation As A Method For Genetic Modification

Can Kinetics Provide Detailed Information About Binding Interactions?

LC/MS/MS Analysis Of Coproporphyrin 1, Coproporphyrin 3 In Human Plasma

A Derivatization-Free LCMS Assay For 4β-hydroxycholesterol

Advancing CGT Delivery, Regulatory Strategy with Axiom's Dr. Remo Moomiaie-Qajar

Advancing Cell Therapy Toward a Functional Cure for T1D With Forthcoming BetaNova's Jonathan Rigby and Will Rust, Ph.D.

Structuring CGT Deals for the Long Term with Troutman Pepper Locke's EA Weeks, J.D., Ph.D.

Shaping Drug Development by Starting with the Disease with Roche's Sylke Poehling, Ph.D.

Why Autoimmune CAR T Needs a New Patient-Centered Playbook with Dr. Panteli Theocharous

Reimagining Solid Tumor Immunotherapy Through Engineered Tregs with CoRegen's Dr. Sonal Gupta

Rewriting the Playbook for Stargardt Disease with Atsena Therapeutics' Shannon Boye, Ph.D.

How Precision Oncology Is Redefining Cancer Drug Development with Aprea Therapeutics' Dr. Oren Gilad

Exploring Dendritic Cell Therapy for Solid Tumors with Diakonos Oncology's Jay Hartenbach

Cell & Gene: The Podcast Presents: Better Biopharma's Editors' Roundtable — A Midyear Look at the 2026 Life Sciences Industry

Why In Vivo Therapies Are Moving Toward the Clinic with Ascidian Therapeutics' Dr. Mike Ehlers

Reimagining In Vivo Gene Editing Through Base Editing and Targeted Delivery with Beam Therapeutics' Gopi Shanker, Ph.D.

Early Development Choices Define Scalability And Product Quality In CGT

Nunc Standard Closed Cell Factory System

Simplifying Bioprocess Data Collection

HyPerforma 5:1 Single-Use Bioreactor (S.U.B.) Setup And Installation Part 3

Simplify Your Process Of Choosing An Optimal Resin

Assuring Viral Safety: Better, Faster, Virus Production

A Collaboration With Zurich University Of Applied Sciences

Stakeholder-Aligned Design For An Intuitive Manufacturing Process

Closing Ancillary Processes: The New Bottleneck In Cell and Gene Therapy

Reimagine Sustainability In Bioprocessing

How MacroGenics Increased mAb Titers By Up To 80% In Scale-Up

Perfusion: Medium Selection And Testing

Process Development For Commercial Readiness: How Soon Is Too Soon?

Lonza Capabilities Update September 2026: Viral Vectors

Regulatory And Biosafety Testing Expertise

Lonza Capabilities Update March 2026: Cell & Gene Therapy

The Power Of Partnerships And The Rise Of iPSC

Early-Phase Whole-Body PK

What Is Causing Limited Bioavailability

Biopharma Resilience: Bionova Scientific Talks Capacity, Speed, And Agility

Closing Ancillary Processes: The New Bottleneck In Cell and Gene Therapy

Selecting The Right CMO For Your Gene Therapy

Bridging The Gap Between Lab Development And GMP Manufacturing

Bioprocessing Solutions For Cell Culture

A Dedicated Team To Safely Store Your Cell And Virus Banks

Thermo Fisher Scientific Single-Use Global Manufacturing Network

Risk Mitigation Strategies

Balancing Innovation With Manufacturability When GMP-Grade Is Unavailable

Regulatory Considerations For An Optimized Cold Chain

BPI Interviews Purification And Pharma Analytics Leader

Perfusion: Planning A Run

An Inside Look At Umoja Biopharma And Bristol Myers Squibb's Cold Chains

Inventory Management, Staff Training, And Timeline Optimization

Overcoming Cryopreservation Challenges

Enabling Large-Scale Lentivirus Manufacturing With A Reliable Stabilizer

Manufacturing Re-Engineered: Unlocking Global Access & Scale Out Economics

Enhancing Particle Recovery And Infectivity In Viral Vector Purification

Smart Manufacturing Decisions For Scalable Gene Therapy Success

From Bench To Bioproduction: Scalable MSC Expansion

Cell Handling Across Cell Types

High-Precision Fluid Management For Cell-Based Applications

Enhancing CGT Analytics And Quality Control With Digital PCR

Non-Viral Delivery Of Complex Cargos For Large-Scale CAR-T Manufacturing

Quantifying Potency In Cell & Gene Therapy

Integrated Reagent Solutions For CAR-T/NK Development And Manufacturing

How Raw Materials, Media Composition, and Process Decisions Shape Therapy Development

Automating Autologous CAR T Manufacturing: Lessons from Mayo Clinic

Scaling Next-Gen MSC Therapies Without Scaling Risk

Solving Vector Yield Challenges in In Vivo CGT

How CGT Developers Can Choose the Right Manufacturing Model for Their Pipeline

Distributed Manufacturing for CGT: Rent, Lease, or Buy in an Era of Overcapacity?

Materials Matter: Ensuring Quality Of CGT Materials

Building Smarter Cell Therapies With AI And Synthetic Biology

2026 Regulatory Roadmap

Driving Efficiency, Reducing Costs In Multi-Modal CGT Manufacturing

Viability On The Line: Defining Minimum Quality For CGT Raw Materials

Designing Early Manufacturing For Long-Term Success In CGT

Building The Future Of Cancer Immunotherapy Through Allogeneic NK Cell Innovation

Redefining CGT With Exosomes And EVs

Advancing Gene Delivery: LNPs, Adenovirus, Lentivirus, And More

Unlocking The Potential Of iPSC Therapies In Regenerative Medicine

Emerging Manufacturing Technologies For Cell Therapies

Optimizing Storage Solutions For Allogeneic iPSCs

2025 CGT Regulatory Outlook

Unlocking The Full Potential Of AAV-Mediated Gene Delivery

Inside The Most Promising Non-Viral Approaches For Genetic Engineering

From Bottleneck To Breakthrough: Reimagining The mRNA Therapeutics Supply Chain

Modernizing CAR-T Manufacturing: Is Point Of Care The Future?

Top Strategies To Reduce Off-Target Effects For Safer Genome Editing

Inside Next-Gen Platforms For Cell Therapy Manufacturing

Unlocking The Future Of Allogeneic Cell Therapy For Oncology

Stem-Cell Derived Therapies: From Source To Site

How To Reduce Batch-to-Batch Variation In Cell Therapy Manufacturing

2024 Regulatory Outlook With FDA's Drs. Peter Marks And Nicole Verdun

Considerations For Investing In Your Gene Therapy's Automation Framework

mRNA For Cancer Immunotherapy: 2024 Outlook

Are We There Yet? Roadmap(s) To Higher Quality AAV

Optimizing Your Cold Chain For Cell Therapies

Stability To Scalability: The Future Of Viral Vector Therapies

Regulating The CGT Workflow To Improve Patient Safety

Driving Down COGS: Automation's Role In Cell Therapy Manufacturing

Major Trends In Next-Gen RNA Engineering

Building An In-House Cell & Gene Manufacturing Facility: Best Practices & Lessons Learned

Scaling Cell Therapies Part 2: Establishing Comparability In Manufacturing

Tackling Cell And Gene Therapies' Top 3 Regulatory Impediments

Evaluating Translational Research Tools For CGTs

Scaling Cell Therapies: Auto vs. Allo

Advancements In Targeted mRNA Delivery

Win The CGT Talent Fight: How To Find And Retain Experts

Kite Pharma's Ultimate Supply Chain Test - A Q&A With Their 4-Exec Panel On Overcoming The Pandemic's Disruption

The Therapeutic Potential Of Exosomes

The Future of CRISPR-Engineered Stem Cell Therapies

Simplifying Bioprocess Data Collection

How The FDA's 2024 Draft Guidances Will Influence CGT Regulation In 2025

Other CGT Regulatory Challenges

Regulatory Challenges And Future Outlook For iPSC Therapies

Inside The Phased, Risk-Based Approach For CGT Materials

CMC Comparability: Transitioning to Commercial Manufacturing with Dr. Nicole Verdun

Ensuring Consistent Removal Of Residual Impurities

Congruence And Divergence In Global Regulatory Approvals

Mitigate Clinical Risk In Cell Therapy Development With A GMP Compliant Process

Challenge #2: Rare Or Ultra-Rare Study Design Considerations And Use Of Existing Data

A Straightforward Path Toward Regulatory Compliance & Data Integrity With Your Microbial Testing Systems

Process Development For Commercial Readiness: How Soon Is Too Soon?

Race To The Regulatory Finish Line: Dr. Nicole Verdun Talks Efficiencies In Platform Technologies

Focal Points for 2024: Dr. Verdun and Dr. Marks Talk Regulatory Challenges for Cell-Based Therapies

How The FDA Strengthens Industry Collaboration

CGT's Main Opportunities To Meet Regulatory Requirements

Strategies To Reduce Regulatory Risks In Gene Therapy

Dr. Peter Marks Talks a Standardized Playbook for Gene Therapy Manufacturing

Bridging Analytical Gaps To Ensure CGT Material Quality

Tackling Cell And Gene Therapies' Top 3 Regulatory Impediments: Audience Q&A

A CDMO Perspective: Bioprocess Automation And Data Management

Prioritizing Quality, Fit, And Supplier Reliability In CGT Materials

2025 CGT Regulatory Outlook | Audience Q&A

Assessing Residuals In Processing And Fill/Finish For iPSCs

Cell And Gene Therapy Innovations

Why Clinical Requirements Change: Dr. Peter Marks on Pre-IND Meeting Pathways

mRNA For Cancer Immunotherapy 2024 Outlook | Audience Q&A

How Past Gene Therapy Approvals Are Shaping the Future with Dr. Peter Marks

Key Regulatory Challenges, Innovations, And Opportunities For CGT In 2025

How The New Administration Could Shape FDA Oversight, Compliance, And Guidance In 2025

MilliporeSigma Bio-Expo Live February 2025: Upstream Bioprocessing

Future Proof Process Design Through Risk-Focused Decisions, Automation Readiness, And Regulatory Pragmatism

Challenge #1: The Changing Regulatory Landscape

Master The 2-Point Calibration Process To Maintain Data Integrity

Regulatory And Biosafety Testing Expertise

Executive Roundtable: Cell Therapy Predictions For 2025 And Beyond

Patient Data's Impact On CMC Robustness

Navigating Global Regulations, Equity Challenges, And The Future Of Patient Access

Lower Variability For Viral Titer Determination

Challenge #3: Lack Of Animal Models

What's New for 2024: Dr. Nicole Verdun Offers a Look Inside The Office Of Therapeutic Products

Making USP Guidance Actionable For CGT Materials

Bioprinting 3D Human Tissue To Discover And Test New Treatments With Viscient Bio's Keith Murphy

Investing In Tomorrow's CNS Breakthroughs With Breyer Capital's Bret Bostwick, M.D.

AI, China, And Biotech Investing With SR One's Simeon George, M.D.

Reprogramming Cancer And Competing With China With Earli's Cyriac Roeding

Growing And Scaling A Radiopharmaceuticals Company With AdvanCell's Philina Lee, Ph.D.

Finding New Opportunities In Obesity With Moonwalk Bioscience's Alex Aravanis, M.D., Ph.D.

Biotech Finance And Investor Update With Independent Board Director Allan Shaw

Funding A Virtual Biotech Without Institutional Capital With Sarcomatrix's David Craig

Picking Biotech Winners Beyond The Hype Cycle With Andera Partners' Olivier Litzka

Biotech Investing At The Earliest Stages With Santé Ventures' Omar Khalil

Getting To A First Product Approval With Celcuity's Brian Sullivan

Cell Therapy Advances And Biotech Leadership With Nkarta's Paul Hastings

Implementing AI And Digital Twins In Bioprocessing With Will Olughu, Ph.D.

Building A Flexible Vaccine Manufacturing Facility With Tonix Pharmaceuticals' Siobhan Fogarty

2026 Regulatory Updates And Operation TrialBlazer

Focusing On Quality Unit Independence With Tatyana Matveeva, Ph.D.

Developing Multi-Targeted T-Cell Engagers With Deck Bio's Johanna Kaufmann

Fixing AAV Recovery With Siren Biotechnology's Nathalie Clément, Ph.D.

Digitalizing The Biopharma Ecosystem With Kat Kozyrytska

Modulating Multispecific Manufacturability With AP Biosciences' JJ You, Ph.D.

The Facility Master Planning Playbook With Herman Bozenhardt

Cell Therapy Without The Cells: Building A Therapeutic Secretome With Noveome Biotherapeutics' Larry Brown, Sc.D.

The Editors' Roundtable: A Midyear Look At The 2026 Life Sciences Industry

Validation Challenges Facing Advanced Single-Use Technologies